On Demand

Opening Session

Welcome by Chairs P. Lampertico and H. Wedemeyer

WHO session | Hepatitis Delta: making a difference in low- and middle-income countries
Moderators: B. Jantsansengee, F.P. Russo and H. Wedemeyer

Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV N. Luhmann

Diagnostics for HDV: what we have and what we need for improving diagnosis in low- and-middle income countries I. Chemin

Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing in Uzbekistan E. Musabaev

HDV diagnosis and treatment in Pakistan and the way forward for LMICs S.S. Hamid

Panel discussion

Session 1 | Virology and Pathogenesis Moderators: M. Dandri and J. Lucifora

Virology: the latest insights S. Urban

Pathogenesis: insights from liver biopsies L. Allweiss

New HBV biomarkers: any role in HDV? B. Testoni

Oral presentation Integrative transcriptomics and epigenomics reveals a viral footprint of chronic HDV infection in HBV co-infected chimeric livers J. Lupberger

Discussion

Session 2 | Diagnosis, Staging, HCC risk and antiviral therapy Moderators: S. Aleman and R. Esteban

HDV-RNA assays: performances and clinical challenges M.P. Anolli

Fibroscan and other non-invasive markers L. Sandmann

PegIFN+NUC: predictors of response M. Brunetto

Oral presentation Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation L. Di Marco

Discussion

Session 3 | Current and new antiviral treatments I Moderators: G. Papatheodoridis and N. Reau

Bulevirtide mono and combo in clinical trials H. Wedemeyer

Bulevirtide in EU: SAVE-D study update E. Degasperi

Bulevirtide in France: multicenter study update H. Fontaine

Bulevirtide for decompensated cirrhosis M. Jachs

Oral presentationEfficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 24 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301 S. Aleman

Discussion

State of the Art Lecture and Prize: “My journey with HDV” C. Yurdaydin (presented by H. Wedemeyer)

Session 4 | Current and new antiviral treatments II Moderators: T. Berg and M. Buti

Bulevirtide in HIV coinfected patients G. D’Offizi

What have we learned from the Lonafarnib and pegIFN lambda trials? T. Asselah

New antivirals for HDV, phase II studies K. Agarwal

What can we learn from HBV trials for HDV cure? M. Levrero

Oral presentationEfficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the Phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants T. Asselah

Discussion

Closing remarks P. Lampertico and H. Wedemeyer

With the unconditional support of

On Demand

This section of the site collects the videos of all the sessions...